An agreement was signed between the University of Ghent and Aicore Life Sciences (ALS) for the further development of a new dosage form (vaginal ring) containing lactic acid for the treatment of (recurrent) bacterial vaginosis.
The University of Ghent owns the fundamental rights to this medical device. The first step of cooperation will be a clinical trial (“proof of concept”) to be performed under ALS’s supervision and financed 50/50 by ALS and the University of Ghent.
Bacterial vaginosis (BV) is a disease of the vagina caused by excessive growth of bacteria and is the most common vaginal infection in women of reproductive age. The disease is caused by an imbalance of naturally occurring bacteria in the vagina. Treatment usually consists of an antibiotic, such as metronidazole.
However, the condition often recurs after treatment. Treatment with antibiotics is under discussion as these should be reserved for more severe infections and as they do not restore the balance of the naturally occurring bacteria. Moreover, no actual cure for recurrent BV exists.
